Protara Therapeutics (TARA) Net Income towards Common Stockholders (2013 - 2026)

Protara Therapeutics' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$18.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 42.99% year-over-year to -$18.0 million; the TTM figure through Mar 2026 stood at -$65.5 million (down 38.43% YoY), while the FY2025 annual figure was -$59.5 million, down 29.89% from the prior year.
• Net Income towards Common Stockholders was -$18.0 million for Q1 2026 at Protara Therapeutics, up from -$18.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $10.8 million in Q1 2022 to a low of -$39.0 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$13.5 million across 5 years, with a median of -$12.6 million in 2025.
• Biggest YoY gain for Net Income towards Common Stockholders was 179.87% in 2022; the steepest drop was 480.98% in 2022.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$39.0 million in 2022, then soared by 73.77% to -$10.2 million in 2023, then sank by 36.98% to -$14.0 million in 2024, then sank by 35.08% to -$18.9 million in 2025, then climbed by 4.97% to -$18.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$18.0 million (Q1 2026), -$18.9 million (Q4 2025), and -$13.3 million (Q3 2025), per Business Quant data.